PLA2G1B cDNA ORF Clone, Mouse, C-Myc tag General Information
Full length Clone DNA of Mouse phospholipase A2, group IB, pancreas with C terminal Myc tag.
Enhanced CMV promoter
Myc Tag Sequence: GAGCAGAAACTCATCTCAGAAGAGGATCTG
T7( 5' TAATACGACTCACTATAGGG 3' )
BGH( 5' TAGAAGGCACAGTCGAGG 3' )
The plasmid is confirmed by full-length sequencing.
Antibiotic in E.coli
Antibiotic in Mammalian cell
Stable or Transient mammalian expression
Storage & Shipping
Each tube contains lyophilized plasmid.
The lyophilized plasmid can be stored at ambient temperature for three months.
**Sino Biological guarantees 100% sequence accuracy of all synthetic DNA constructs we deliver, but we do not guarantee protein expression in your experimental system. Protein expression is influenced by many factors that may vary between experiments or laboratories.**
PLA2G1B cDNA ORF Clone, Mouse, C-Myc tag Alternative Names
Pla2a cDNA ORF Clone, Mouse;sPLA2IB cDNA ORF Clone, Mouse
PLA2G1B Background Information
phospholipase A2, also known as Phosphatidylcholine 2-acylhydrolase 1B, Group IB phospholipase A2, PLA2 and PLA2G1B, is a secreted protein which belongs to the phospholipase A2 family. Phospholipase A2 / PLA2G1B catalyzes the release of fatty acids from glycero-3-phosphocholines. The best known varieties are the digestive enzymes secreted as zymogens by the pancreas of mammals. Sequences of pancreatic Phospholipase A2 / PLA2G1B enzymes from a variety of mammals have been reported. One striking feature of these enzymes is their close homology to venom phospholipases of snakes. Other forms of Phospholipase A2 / PLA2G1B have been isolated from brain, liver, lung, spleen, intestine, macrophages, leukocytes, erythrocytes, inflammatory exudates, chondrocytes, and platelets. Mice lacking in Phospholipase A2 / PLA2G1B are resistant to obesity and diabetes induced by feeding a diabetogenic high-fat/high-carbohydrate diet. Oral supplementation of a diabetogenic diet with the PLA2G1B inhibitor methyl indoxam effectively suppresses diet-induced obesity and diabetes. PLA2G1B inhibition may be a potentially effective oral therapeutic option for treatment of obesity and diabetes.
phospholipase A2, group IB (pancreas)
Labonté,E.D. et al., 2006, Diabetes. 55 (4) :935-41. Mounier,C.M. et al.,2008, Br J Cancer. 98 (3):587-95. Hui,D.Y. et al., 2009, Br J Pharmacol. 157 (7):1263-9. Labonté,E.D. et al., 2010, FASEB J. 24 (7):2516-24.